A Study to Investigate the Cardiovascular Safety of Apricitabine in Healthy Subjects

This study has been completed.
Sponsor:
Information provided by:
Avexa
ClinicalTrials.gov Identifier:
NCT00334659
First received: June 6, 2006
Last updated: June 21, 2011
Last verified: June 2011
  Purpose

The purpose of this study is to confirm that apricitabine does not induce any clinically significant effect upon electrocardiogram (ECG) parameters at doses consistent with the maximum exposure expected to occur in clinical practice.


Condition Intervention Phase
HIV Infections
Drug: apricitabine
Phase 1

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety Study
Intervention Model: Crossover Assignment
Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Official Title: A Double-blind, Placebo-controlled, Positive Controlled, Randomized, Crossover Study to Investigate the Cardiovascular Safety of Apricitabine in Healthy Subjects

Resource links provided by NLM:


Further study details as provided by Avexa:

Primary Outcome Measures:
  • QTc at individual Day 7 post-dose Tmax as determined by concurrent pharmacokinetic (PK) analysis for apricitabine [ Time Frame: day 7 ] [ Designated as safety issue: Yes ]
  • The maximum Day 7 QTc increase from baseline observed between 1 to 4 hours post-dose, using time-matched ECG assessments [ Time Frame: day 7 ] [ Designated as safety issue: Yes ]
  • The average Day 7 QTc observed between 1 to 4 hours post-dose [ Time Frame: day 7 ] [ Designated as safety issue: Yes ]

Enrollment: 37
Study Start Date: June 2006
Study Completion Date: August 2006
Primary Completion Date: August 2006 (Final data collection date for primary outcome measure)
  Eligibility

Ages Eligible for Study:   18 Years to 65 Years
Genders Eligible for Study:   Male
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Healthy male subjects 18 - 65 years of age, inclusive.
  • Body mass index (BMI) between 18-30 kg/m2, inclusive, and a total body weight > 50 kg.
  • No clinically significant medical history.
  • No clinically significant findings on complete physical examination, including blood pressure, pulse rate and 12-lead ECG.
  • Normal clinical safety laboratory results at screening.
  • Willing and able to sign an informed consent document indicating understanding the purpose of and procedures required for the study and willingness to participate in the study.
  • Willing and able to stay in the clinic for the in-patient activities required by the protocol.

Exclusion Criteria:

  • Evidence of clinically relevant pathology that could interfere with the study results or put the subject's safety at risk.
  • Current or recurrent disease that may affect the action, absorption or disposition of the study treatment, or clinical or laboratory assessments.
  • Current or relevant previous history of serious, severe or unstable (acute or progressive) physical or psychiatric illness, any medical disorder requiring treatment or that may make the subject unlikely to fully complete the study, or any condition that presents undue risk from the study treatment or procedures.
  • History of febrile illness within the 5 days prior to the first dose.
  • Positive Hepatitis B surface antigen, Hepatitis C antibody or HIV test result at screening visit.
  • Use of any prescription medication within 7 days or 5 half-lives (whichever is longer) prior to the first dose of trial medication or during the study. As an exception, acetaminophen may be used at doses of ≤ 1 g/day.
  • Use of any over-the-counter (OTC) medication within 7 days or 5 half-lives (whichever is longer) prior to or during the study. Herbal supplements (including herbal weight-loss or "metabolism booster" therapies) must be discontinued 28 days prior to the first dose of trial medication.
  • Known or suspected intolerance or hypersensitivity to the study drugs, closely related compounds or any of their stated ingredients.
  • Subjects with a history of regular alcohol consumption exceeding 14 drinks/week (1 drink = 5 ounces [150 ml] of wine, 12 ounces [360 ml] of beer or 1.5 ounces [45 ml] of hard liquor) or illicit substance abuse within 6 months of screening.
  • Positive screen for alcohol or drugs of abuse during screening visit or at study check-in.
  • History or evidence of routine use of tobacco or nicotine-containing products in excess of 5 cigarettes per day (or equivalent).
  • Participated in a clinical study involving an investigational drug within 30 days or 5 half-lives (whichever is longer) prior to study drug administration.
  • Blood donation of one pint or more within 56 days of the start of the study.
  • Plasmapheresis or plasma donation within 30 days of the start of the study.
  • Single 12-lead ECG demonstrating QTc > 450 msec at screen. A single repeat ECG may be done at the investigator's discretion.
  • Any condition that in the opinion of the investigator would complicate or compromise the study, or the well-being of the subject.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00334659

Locations
United States, Michigan
Jasper Clinic Inc.
Kalamazoo, Michigan, United States, 49007
Sponsors and Collaborators
Avexa
Investigators
Study Director: Susan W Cox, PhD Avexa
  More Information

No publications provided

Responsible Party: Susan Cox, Avexa
ClinicalTrials.gov Identifier: NCT00334659     History of Changes
Other Study ID Numbers: AVX-101
Study First Received: June 6, 2006
Last Updated: June 21, 2011
Health Authority: United States: Food and Drug Administration

Keywords provided by Avexa:
HIV-1 Infection

Additional relevant MeSH terms:
Acquired Immunodeficiency Syndrome
HIV Infections
Infection
Immune System Diseases
Immunologic Deficiency Syndromes
Lentivirus Infections
RNA Virus Infections
Retroviridae Infections
Sexually Transmitted Diseases
Sexually Transmitted Diseases, Viral
Slow Virus Diseases
Virus Diseases

ClinicalTrials.gov processed this record on October 30, 2014